|Earth Science Tech, Inc. (ETST) Sets Testing Dates for Cannabinoid-Based Products|
- Quebec grant will help develop its cannabinoid products; ETST testing will commence in 4Q2018 on formula patents aimed at preventing cancer and other diseases
- ETST will apply for trademark, finalize packaging for debut of medical device designed to diminish sexually transmitted infections; women will be target audience for this product
- Company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing its high-grade line of hemp cannabidiol
Earth Science Tech, Inc. (OTC: ETST) has established testing dates for three of its cannabinoid-based (CBD) products. Funded by a grant from Quebec, ETST is now prototyping three CBD patent formulas. A superfood edible is expected to be ready for 4Q2018. The company is scheduled to begin in vitro testing on its first batch of formulas in the summer of 2019, with a goal of demonstrating the superior antioxidant properties and anti-proliferative effects on breast cancer cells, it announced (http://nnw.fm/cPK5W).
The goal of these products is to stop inflammation, maintain quality of life, and help prevent cancer and other degenerative diseases. The branding of these three products is in the planning stage.
ETST, a biotech company based in Doral, Florida, has repositioned its line of full-spectrum CBD offerings. It also conducts R&D for low cost, non-invasive medical devices as it concentrates on manufacturing, marketing and distributing its cannabinoid products to the nutraceutical and pharmaceutical markets.
Its MSN-2 medical device is in its final stage prior to the launch of large-scale marketing. ETST is working with Montreal-based Acceleration, Design et Innovation Inc. to aid in the preparation and introduction. Final packaging is being designed to appeal to its target global audience of women. The device is developed to prevent chlamydia and other sexually transmitted infections.
“The official launch of this medical device is a little like giving birth,” Dr. Michel Aube, CEO and chief science officer of ETST, stated in a news release. “It will be unique in the marketplace and we are branding this device globally. The commercial name will be announced soon, as we are in the process of trademark protection for the logo and name.”
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit, accepting grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also has subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company formed to provide ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer